title: Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT.
abstract: OBJECTIVE
  The aim of the study was to compare the diagnostic accuracy of (18)F-fluorodeoxyglucose (FDG) PET/CT versus standard planar bone scintigraphy (BS) and (18)F-labelled NaF ((18)F) PET for the detection of bone metastases (BM) in non-small cell lung cancer (NSCLC).
  
  
  METHODS
  (18)F-FDG PET/CT was performed in 126 patients with NSCLC. Within 7 days BS (n = 58) or (18)F PET (n = 68) was performed. (18)F-FDG PET/CT, BS and (18)F PET were evaluated by two experienced readers. Lesions were graded on a scale from 1 (definite BM) to 5 (degenerative lesion), and equivocal lesions were determined as indifferent (grade 3).
  
  
  RESULTS
  A total of 92 patients showed degenerative lesions (grade 4/5) on PET/CT, BS or (18)F PET. In 34 patients (27%) BM lesions were diagnosed (grades 1 and 2). In 13 of 18 patients BM were concordantly diagnosed with PET/CT and (18)F PET. PET/CT showed more BM compared to (18)F PET (53 vs 40). In one patient one osteolytic BM was false-negative on (18)F PET. However, (18)F PET identified four patients with BM compared to negative findings on PET/CT. Of 16 patients, 11 had concordant findings of BM on PET/CT and BS. In three patients BS was false-negative and in two patients BM were diagnosed as indifferent.
  
  
  CONCLUSIONS
  Integrated (18)F-FDG PET/CT is superior to BS in the detection of osteolytic BM in NSCLC. Thus, PET/CT may obviate the need to perform additional BS or (18)F PET in the staging of NSCLC, which significantly reduces costs.
authors.affiliation: Medical Clinic II, University Hospital, Ulm, Germany. stkrueger@ukaachen.de
authors.forename: Stefan
authors.initials: S
authors.lastname: Krüger
authors.forename: Andreas K
authors.initials: AK
authors.lastname: Buck
authors.forename: Felix M
authors.initials: FM
authors.lastname: Mottaghy
authors.forename: Ellen
authors.initials: E
authors.lastname: Hasenkamp
authors.forename: Sandra
authors.initials: S
authors.lastname: Pauls
authors.forename: Christian
authors.initials: C
authors.lastname: Schumann
authors.forename: Thomas
authors.initials: T
authors.lastname: Wibmer
authors.forename: Tobias
authors.initials: T
authors.lastname: Merk
authors.forename: Vinzenz
authors.initials: V
authors.lastname: Hombach
authors.forename: Sven N
authors.initials: SN
authors.lastname: Reske
mesh_terms: D001859:Bone Neoplasms / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000556:secondary*; D001842:Bone and Bones / Q000000981:diagnostic imaging*; D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology; D005459:Fluorides / Q000737:chemistry; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology*; D049268:Positron-Emission Tomography; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D013669:Technetium Tc 99m Medronate; D014057:Tomography, X-Ray Computed
chemical_list: D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D005459:Fluorides; D013669:Technetium Tc 99m Medronate